World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2025

D-Index & Metrics

Immunology

D-Index
140
Citations
64984
World Ranking
165
National Ranking
110

Medicine

D-Index
141
Citations
70756
World Ranking
1634
National Ranking
951

David M. Goldenberg publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David M. Goldenberg sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 1,078 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David M. Goldenberg D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David M. Goldenberg sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 140 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Immunology in United States Leader Award

Overview

David M. Goldenberg is affiliated with Immunomedics in the United States and has a substantial publication record in the field of Medicine, with a particular focus on Oncology. Their research spans several subfields including Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Surgery, and Epidemiology.

The scientist's work addresses key topics such as:

  • HER2/EGFR in Cancer Research
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Treatment and Pharmacology
  • Advanced Breast Cancer Therapies
  • LGBTQ Health, Identity, and Policy
  • Tracheal and airway disorders
  • Colorectal Cancer Treatments and Studies

David M. Goldenberg has contributed to multiple publications in prominent venues, including:

  • Annals of Oncology
  • Cancer Research
  • Oncotarget
  • npj Breast Cancer
  • Journal of Nuclear Medicine

The scientist has collaborated frequently with several co-authors, such as Robert T. Sataloff, Robert M. Sharkey, Edward Fisher, Ehab Y. Hanna, and Jonas T. Johnson.

Selected recent papers authored or co-authored by David M. Goldenberg include:

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial, 2021, Annals of Oncology
  • Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer, 2021, Annals of Oncology
  • Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial, 2020, Annals of Oncology
  • Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy, 2020, Expert Opinion on Biological Therapy

Best Publications

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

    D.M. Goldenberg;F. DeLand;E. Kim;S. Bennett

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

    David M. Goldenberg;Thomas M. Cardillo;Serengulam V. Govindan;Edmund A. Rossi

  • Ionization−Reactivity Relationships for Cysteine Thiols in Polypeptides†

    Grzegorz Bulaj;Tanja Kortemme;David P. Goldenberg

  • CYSTIC LYMPH NODE METASTASIS IN PATIENTS WITH HEAD AND NECK CANCER: AN HPV-ASSOCIATED PHENOMENON

    David Goldenberg;Shahnaz Begum;William H. Westra;Zubair Khan

  • Immunotherapy of B-cell malignancies using anti-CD22 antibodies

    David M. Goldenberg

  • A Novel Method of 18F Radiolabeling for PET

    William J. McBride;Robert M. Sharkey;Habibe Karacay;Christopher A. D'Souza

  • Targeted Therapy of Cancer with Radiolabeled Antibodies

    David M Goldenberg

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Oral complications of radiotherapy.

    James J Sciubba;David Goldenberg

  • Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy

    David M. Goldenberg;Robert M. Sharkey;Giovanni Paganelli;Jacques Barbet

  • Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen

    D M Goldenberg;E E Kim;F H DeLand;S Bennett

  • First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

    Alexander N. Starodub;Allyson J. Ocean;Manish A. Shah;Michael J. Guarino

  • Kinetic role of a meta-stable native-like two-disulphide species in the folding transition of bovine pancreatic trypsin inhibitor☆

    T.E. Creighton;D.P. Goldenberg

  • Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

    Edmund A. Rossi;David M. Goldenberg;Thomas M. Cardillo;William J. McBride

  • Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

    Thomas Dörner;Joerg Kaufmann;William A Wegener;Nick Teoh

  • Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations

    Thomas M. Behr;David M. Goldenberg;Wolfgang Becker

  • Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

    Thomas M. Cardillo;Serengulam V. Govindan;Robert M. Sharkey;Preeti Trisal

  • Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers

    Rosalyn D Blumenthal;Evelyn Leon;Hans J Hansen;David M Goldenberg

  • Tracheotomy Complications: A Retrospective Study of 1130 Cases:

    David Goldenberg;Eliav Gov Ari;Avishay Golz;Joshua Danino

  • Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

    John P. Leonard;Morton Coleman;Jamie C. Ketas;Amy Chadburn

Frequent Co-Authors

Robert M. Sharkey
Robert M. Sharkey University of Fukui
Chien-Hsing Chang
Chien-Hsing Chang Northwestern University
Hans J. Hansen
Hans J. Hansen Eisai (Japan)
Edmund A. Rossi
Edmund A. Rossi Immunomedics (United States)
Gary L. Griffiths
Gary L. Griffiths National Institutes of Health
Otto C. Boerman
Otto C. Boerman Radboud University
Wim J.G. Oyen
Wim J.G. Oyen Humanitas University
Ivan D. Horak
Ivan D. Horak Freie Universität Berlin
Jacques Barbet
Jacques Barbet University of Nantes
Aditya Bardia
Aditya Bardia Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with various healthcare and nursing pathways. For those interested in expanding their qualifications quickly, exploring accelerated np programs can be a strategic move. These programs offer an efficient route for nurses aiming to become Nurse Practitioners, allowing them to deepen their clinical expertise and impact in immunology-related fields.

If you don’t have a nursing background but wish to enter this domain, consider enrolling in online bsn programs for non nurses. These programs help non-nurses acquire foundational nursing knowledge, which is crucial for immunology research and patient care roles.

For quicker entry into nursing alongside immunology interests, candidates often look for accelerated nursing programs near me. These are designed to fast-track your education, enabling a faster transition into the workforce.

Additionally, accredited lpn programs easy to get into provide foundational nursing credentials and serve as a stepping stone for further specialization relevant to immunology careers.

Best Scientists Citing David M. Goldenberg

Trending Scientists

Recently Published Articles